LBL-076 / Leads Biolabs - LARVOL DELTA

Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma (ASH 2025) - "Although CD38 expression is downregulated during daratumumabtreatment, it gradually rebounds to baseline within months after treatment cessation. LBL-076 is a first-in-class trispecific TCE to co-target GPRC5D, CD38 and CD3, designed to enhancecytotoxicity against MM cells. Its molecular architecture is rationally optimized: the GPRC5D arm carriesprecisely tuned valency, and the CD38 arm is positioned distally to maximize tumor-directed cytotoxicitywhile curbing CD38-mediated on-target, off-tumor toxicity. Simultaneous targeting of two validated TAAsby a single TCE, LBL-076 delivers enhanced cytotoxic potency across the full spectrum of GPRC5D andCD38 expression levels in both in vitro and in vivo models, indicating significant therapeutic potential totransform outcomes for MM patients relapsed or refractory to single-target therapies."

IO biomarker • Trispecific • Hematological Malignancies • Multiple Myeloma • GPRC5D